Despite improved survival rates and guideline recommendations, many eligible patients with metastatic Merkel cell carcinoma are not receiving immunotherapy.
A large study supports the use of stereotactic radiosurgery in patients with 15 or more brain metastases, finding improved cognitive outcomes and comparable survival to whole brain radiation.
Clinical trial holds delay therapies getting to market and may be on the rise in oncology. But there's a lot the public doesn't know about how often these holds happen and why.
There is no increased relapse risk in patients with multiple sclerosis and comorbid cancer who are taking checkpoint inhibitor therapy, results of a small study suggest.
With sparse guidance regarding best practices for IHC in melanoma diagnosis, more research is needed to optimize use of IHC in this setting, according to the authors.